In Vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4608-4613

  Prokocimer, Philippe ^a   Bien, Paul ^a   DeAnda, Carisa ^a,c   Pillar, Chris M ^b   Bartizal, Ken ^a  

^a Trius Therapeutics Inc   (United States)

^b Eurofins Medinet Inc   (Germany)

^c Micromyx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; LINEZOLID; TEDIZOLID;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; ERADICATION THERAPY; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; SKIN; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS; TETRAZOLES;

EID: 84865432225     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00458-12     Document Type: Article

References (34)

1. Appelbaum PC. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408. (Pubitemid 47498971)
2. Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52:1570-1572. (Pubitemid 351522039)
3. Betriu C, et al. 2010. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob. Agents Chemother. 54:2212-2215.
4. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl 5):S344-S349. (Pubitemid 351717321)
5. Brown SD, Traczewski MM. 2010. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob. Agents Chemother. 54:2063-2069.
6. Chambers HF, Moellering RC, Jr, Kamitsuka P. 2008. Clinical decisions. Management of skin and soft-tissue infection. N. Engl. J. Med. 359:1063-1067.
7. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A08, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disk susceptibility tests. Approved standard M02-A10, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. 18th informational supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. 2005. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49:5024-5032. (Pubitemid 41778916)
11. Edelsberg J, et al. 2009. Trends in US hospital admissions for skin and soft tissue infections. Emerg. Infect. Dis. 15:1516-1518.
12. Fritsche TR, Sader HS, Jones RN. 2007. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn. Microbiol. Infect. Dis. 58:19-26. (Pubitemid 46694276)
13. Gorak EJ, Yamada SM, Brown JD. 1999. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin. Infect. Dis. 29:797-800. (Pubitemid 30256370)
14. Han LL, et al. 2007. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J. Clin. Microbiol. 45:1350-1352. (Pubitemid 46626515)
15. Herold BC, et al. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598. (Pubitemid 28110205)
16. Jones RN. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42(Suppl 1):S13-S24. (Pubitemid 41832061)
17. Jones RN, Fritsche TR, Sader HS, Ross JE. 2007. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59:309-317. (Pubitemid 350016703)
18. Jones RN, et al. 2009. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis. 65:404-413.
19. King MD, et al. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317. (Pubitemid 46768185)
20. Livermore DM, Mushtaq S, Warner M, Woodford N. 2009. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J. Antimicrob. Chemother. 63:713-715.
21. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:3453-3460.
22. McClure JA, et al. 2006. Novel multiplex PCR assay for detection of the staphylococcal virulence marker Panton-Valentine leukocidin genes and simultaneous discrimination of methicillin-susceptible from -resistant staphylococci. J. Clin. Microbiol. 44:1141-1144.
23. Mendes RE, et al. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246. (Pubitemid 351758569)
24. Mera RM, et al. 2011. Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion. Microb. Drug Resist. 17:321-328.
25. Merlino JI, Malangoni MA. 2007. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve. Clin. J. Med. 74(Suppl 4):S21-S28.
26. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. 2007. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 57:7-13. (Pubitemid 44908825)
27. Morales G, et al. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50:821-825.
28. Moran GJ, et al. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
29. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.
30. Patel M, Waites KB, Moser SA, Cloud GA, Hoesley CJ. 2006. Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J. Clin. Microbiol. 44:2481-2484. (Pubitemid 44092415)
31. Prokocimer P, et al. 2011. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592.
32. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. 2009. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236-3239.
33. Shaw KJ, et al. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442-4447.
34. Stryjewski ME, Chambers HF. 2008. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl 5):S368-S377. (Pubitemid 351717324)